DeepMed Research

NATIONAL INSTITUTE ON DRUG ABUSE AND ADDICTION

🇵🇰Pakistan

Country: 🇵🇰Pakistan

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Treatment of Heroin and Cocaine With Methadone Maintenance and Contingency Management

Phase 1

Completed

Conditions: Opiate-Related Disorders
Cocaine-Related Disorders

Interventions: Behavioral: Contingency Management
Drug: Methadone
Behavioral: Contingency Management/Noncontingent Incentives
Drug: Methadone dose

First Posted Date: 2006-02-15

Last Posted Date: 2019-12-17

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 140

Registration Number: NCT00292110

Locations: 🇺🇸
National Institute on Drug Abuse, Baltimore, Maryland, United States

Real Time Assessment of Drug Craving, Use, and Abstinence During Outpatient: A Development and Feasibility Study

Completed

Conditions: Cocaine Addiction
Opiate Addiction

First Posted Date: 2006-02-15

Last Posted Date: 2018-04-05

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 230

Registration Number: NCT00292136

Locations: 🇺🇸
National Institute on Drug Abuse, Baltimore, Maryland, United States

Combined Behavioral and Pharmacologic Treatment of Polydrug Abuse

Phase 1

Completed

Conditions: Opioid Dependence
Cocaine Abuse

First Posted Date: 2006-02-15

Last Posted Date: 2017-01-12

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 200

Registration Number: NCT00292123

Smoking and Alcohol Initiation

Completed

Conditions: Smoking
Alcohol Drinking

First Posted Date: 2006-01-04

Last Posted Date: 2017-01-11

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 2600

Registration Number: NCT00271843

Locations: 🇺🇸
California State University, Fullerton, California, United States

A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1

Phase 1

Conditions: Amphetamine-Related Disorders

First Posted Date: 2005-12-21

Last Posted Date: 2017-01-11

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 30

Registration Number: NCT00267657

Locations: 🇺🇸
U of CA, San Francisco, San Francisco, California, United States

Assessment of Interactions Between Intravenous Methamphetamine and Modafinil - 1

Phase 1

Conditions: Amphetamine-Related Disorders

First Posted Date: 2005-12-14

Last Posted Date: 2017-01-11

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 16

Registration Number: NCT00265278

Locations: 🇺🇸
U of CA, San Francisco, San Francisco, California, United States

Assessment of Potential Interactions Between Intravenous Cocaine and Atomoxetine - 1

Phase 1

Completed

Conditions: Cocaine-Related Disorders

First Posted Date: 2005-12-14

Last Posted Date: 2017-01-12

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 16

Registration Number: NCT00265265

Locations: 🇺🇸
Uniformed Services University of Health Science, Bethesda, Maryland, United States

Emergency Department Initiated Tobacco Treatment (EDITT)

Phase 1

Completed

Conditions: Tobacco Use

First Posted Date: 2005-11-15

Last Posted Date: 2017-01-11

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 75

Registration Number: NCT00252902

Locations: 🇺🇸
Cooper University Hospital, Camden, New Jersey, United States

Medication Adherence Therapy for Opioid Abusing Pain Patients

Phase 1

Completed

Conditions: Prescription Opioid Abuse
Pain
Chronic Disease

Interventions: Drug: Methadone

First Posted Date: 2005-11-07

Last Posted Date: 2017-01-10

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 36

Registration Number: NCT00249587

Locations: 🇺🇸
Behavioral Science Research Unit, New York, New York, United States

Bridging Active Heroin Users to Hepatitis C Treatment Using Buprenorphine - 1

Not Applicable

Completed

Conditions: Heroin Dependence
Hepatitis C

Interventions: Drug: Buprenorphine/naloxone
Drug: pegInterferon

First Posted Date: 2005-11-07

Last Posted Date: 2017-01-16

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 10

Registration Number: NCT00249574

Locations: 🇺🇸
O.A.S.I.S., Oakland, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy